ID: ALA3422652

Max Phase: Preclinical

Molecular Formula: C19H19N5O2

Molecular Weight: 349.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCn1c(N)c(C#N)c2cc(Oc3ccc(NC(=O)CN)cc3)ccc21

Standard InChI:  InChI=1S/C19H19N5O2/c1-2-24-17-8-7-14(9-15(17)16(10-20)19(24)22)26-13-5-3-12(4-6-13)23-18(25)11-21/h3-9H,2,11,21-22H2,1H3,(H,23,25)

Standard InChI Key:  MSVRQAUNRZMPBR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 349.39

Molecular Weight (Monoisotopic): 349.1539

AlogP: 2.80

#Rotatable Bonds: 5

Polar Surface Area: 119.09

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.87

CX Basic pKa: 7.98

CX LogP: 1.58

CX LogD: 0.90

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.65

Np Likeness Score: -1.40

References

1. Boyd S, Brookfield JL, Critchlow SE, Cumming IA, Curtis NJ, Debreczeni J, Degorce SL, Donald C, Evans NJ, Groombridge S, Hopcroft P, Jones NP, Kettle JG, Lamont S, Lewis HJ, MacFaull P, McLoughlin SB, Rigoreau LJ, Smith JM, St-Gallay S, Stock JK, Turnbull AP, Wheatley ER, Winter J, Wingfield J..  (2015)  Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3.,  58  (8): [PMID:25849762] [10.1021/acs.jmedchem.5b00352]

2. Bürli RW, Wei H, Ernst G, Mariga A, Hardern IM, Herlihy K, Cross AJ, Wesolowski SS, Chen H, McKay RDG, Weinberger DR, Brandon NJ, Barrow JC..  (2018)  Novel inhibitors of As(III) S-adenosylmethionine methyltransferase (AS3MT) identified by virtual screening.,  28  (19): [PMID:30170942] [10.1016/j.bmcl.2018.08.012]

Source

Source(1):

• Scientific Literature